

March 5, 2019

BSE Limited
P. J. Towers
Dalal Street, Fort
Mumbai – 400 001

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex,
Bandra (E)
Mumbai – 400 051

Dear Sir / Madam,

Sub: Issuance of rated unsecured bonds of US\$200 million by our wholly-owned subsidiary Jubilant Pharma Limited (a company incorporated under the laws of Singapore), outside India, under Regulation S of the U.S. Securities Act of 1933, as amended.

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, and further to the disclosures made to the stock exchanges earlier in this regard, we wish to inform you that our material wholly-owned subsidiary, Jubilant Pharma Limited (a company incorporated under the laws of Singapore) (“**JPL**”) has successfully completed today i.e. March 5, 2019, the issuance of rated unsecured bonds (the “**Notes**”) to institutional investors outside India under Regulation S of the U.S. Securities Act of 1933, as amended, bearing interest at 6.00% per annum. The Notes were issued at par in a principal amount of US\$200 million and will mature in March, 2024.

The Joint Global Coordinators, Joint Lead Managers and Joint Bookrunners to the issue of the Notes are DBS Bank Ltd., J.P. Morgan (S.E.A.) Limited and UBS AG, Singapore Branch.

The above is for your information and records. The Company will provide further updates in this regard, if and when necessary.

We request you to take the same on record.

Thanking you,

Yours Faithfully,
For Jubilant Life Sciences Limited

Rajiv Shah
Company Secretary

This announcement is not for distribution in or into the United States. This announcement is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States unless they are registered or are exempt from registration. Any public offering of securities to be made in the United States would be made by means of a prospectus that would contain detailed information about the issuer, their management and their financial statements in compliance with all relevant laws. The issuer does not have any current intention to make any public offering of, or to register, any securities in the United States.

A Jubilant Bhartia Company

OUR VALUES



Jubilant Life Sciences Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubl.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223,
UP, India
CIN : L24116UP1978PLC004624